Nalbuphine Hydrochloride ER is a small molecule commercialized by Trevi Therapeutics, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 16 clinical trials, of which 10 were completed, 4 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Nalbuphine Hydrochloride ER’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Nalbuphine Hydrochloride ER is expected to reach an annual total of $243 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Nalbuphine Hydrochloride ER Overview
Nalbuphine hydrochloride ER (T-111) is under development for the treatment of chronic pruritus in prurigo nodularis, pruritis in chronic liver disease, idiopathic pulmonary fibrosis, chronic cough in idiopathic pulmonary fibrosis patients. The drug candidate is administered through oral route as a tablet. The drug candidate is an extended release formulation of an existing compound nalbuphine hydrochloride. Nalbuphine is a phenanthrene derivative which targets opioid kappa and mu receptors and it was also under development for the treatment of atopic dermatitis. It was also under development for atopic dermatitis and uremic pruritus, levodopa-induced dyskinesia (LID) in Patients with Parkinson’s Disease. .
Trevi Therapeutics Overview
Trevi Therapeutics is a clinical-stage biopharmaceutical company. It is developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi Therapeutics‘s Haduvio is a dual ?-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Trevi Therapeutics is headquartered in New Haven, Connecticut, the US.
The operating loss of the company was US$33.9 million in FY2023, compared to an operating loss of US$29.9 million in FY2022. The net loss of the company was US$29.1 million in FY2023, compared to a net loss of US$29.2 million in FY2022.
For a complete picture of Nalbuphine Hydrochloride ER’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
